Cleared Traditional

K811821 - CAROTID ARTERY CLAMP & TOOLS (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K811821 · New England Surgical Instrument Corp. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1981
Decision
87d
Days
Class 2
Risk

K811821 is an FDA 510(k) clearance for the CAROTID ARTERY CLAMP & TOOLS. Classified as Clamp, Carotid Artery (product code HCE), Class II - Special Controls.

Submitted by New England Surgical Instrument Corp. (Mchenry, US). The FDA issued a Cleared decision on September 24, 1981 after a review of 87 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5175 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all New England Surgical Instrument Corp. devices

Submission Details

510(k) Number K811821 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 29, 1981
Decision Date September 24, 1981
Days to Decision 87 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
61d faster than avg
Panel avg: 148d · This submission: 87d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HCE Clamp, Carotid Artery
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5175
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.